Abstract
Objectives:
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Prevalence estimates of IBS vary widely, from 10 to 15%, in the U.S. However, few studies have examined constipation predominant IBS (IBS-C), a subtype of IBS. The aim of this study was to assess the effect of IBS-C on health-related quality of life (HRQOL), work productivity and activity impairment, and health care resource use.
Methods:
Using data from the 2007 U.S. National Health and Wellness Survey, IBS-C patients (n = 789) were compared to a propensity-score matched comparison group (n = 789). Differences between the groups were examined on HRQOL (SF-12v2), work productivity and activity impairment (WPAI questionnaire), and self-reported resource use in the last 6 months.
Results:
Patients with IBS-C reported significantly lower levels of HRQOL (physical component summary score: 41.55 [95% CI: 40.72–42.37] versus 44.49 [95% CI: 43.67–45.31]; mental component summary score: 40.58 [95% CI: 39.75–41.40] vs. 45.87 [95% CI: 45.04–46.70]) and significantly higher mean levels of presenteeism (31.72% [95% CI: 28.25%–35.61%] vs. 21.43% [95% CI: 19.03%–24.15%]), overall work impairment (35.54% [95% CI: 31.76%–39.76%] vs. 25.29% [95% CI: 22.59%–28.30%]), and activity impairment (45.78% [95% CI: 43.08%–48.66%] vs. 33.03% [95% CI: 31.08%–35.11%]) than matched comparators (all P values < 0.01). Patients with IBS-C reported significantly more provider visits (8.07 [95% CI: 7.38–8.82] vs. 5.55 [95% CI: 5.07–6.08]) and emergency room visits (0.57 [95% CI: 0.46–0.70] vs. 0.36 [95% CI: 0.29–0.45]) in the past 6 months (all Ps < 0.01). No statistically significant differences between the groups were observed in absenteeism or the number of the days hospitalized.
Conclusions:
IBS-C was associated with poorer HRQOL, greater work productivity loss and activity impairment, and greater healthcare resource use. Limitations include the study’s cross-sectional design and its self-reported nature. Nevertheless, improved management of IBS-C may reduce the humanistic and economic burden of the condition and benefit patients, employers, and the healthcare system.
Transparency
Declaration of funding
The NHWS was fielded by Kantar Health. The analysis and preparation of the manuscript using NHWS was funded by Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA.
Declaration of financial/other relationships
M.D. and J.-S.W. are employees of Kantar Health. S.C.B. was an employee of Kantar Health at the time this study was conducted and the manuscript was prepared. R.M. is an employee of Takeda Pharmaceuticals International, Inc. S.X.S. was an employee of Takeda Pharmaceuticals International, Inc. at the time the study was conducted and the manuscript was prepared.
CMRO peer reviewers may have received honoraria for their review work. The peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.